Healthcare / BiotechnologyShanghai
$12.91
-0.24 (-1.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $33.9M · quality 40.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
41.6x
↑EV/EBITDA
14.1x
↑ROE
3.9%
↑Gross Margin
44.8%
↓Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.5%
FCF CAGR
—
FCF margin
2.5%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.37B · net income $69.8M · FCF $33.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.37B | $1.37B | $1.32B | $1.20B | $1.16B |
| Net Income | $69.8M | $69.8M | $62.6M | $80.7M | $69.8M |
| EBITDA | $258.3M | $258.3M | $256.3M | $211.5M | $175.1M |
| EPS | 0.28 | 0.28 | 0.25 | 0.32 | 0.27 |
| Gross Margin | 44.8% | 44.8% | 45.0% | 46.2% | 43.2% |
| Operating Margin | 9.8% | 9.8% | 11.1% | 11.8% | 10.8% |
| Net Margin | 5.1% | 5.1% | 4.7% | 6.7% | 6.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.37 | 0.42 | 0.32 |
| Current Ratio | 1.19 | 1.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $33.9M | $33.9M | $90.7M | $-62.1M | $-246.7M |
| Returns | |||||
| ROE | 3.9% | 3.9% | 3.6% | 4.7% | 4.2% |
| Valuation | |||||
| P/E | 41.65 | 41.65 | 46.44 | 44.44 | 50.67 |
| EV/EBITDA | 14.15 | 14.15 | 12.86 | 19.25 | 21.98 |
| P/B | 1.81 | 1.81 | 1.67 | 2.10 | 2.15 |
| Growth & Yield | |||||
| Revenue Growth | 3.4% | 3.4% | 10.2% | 3.1% | — |
| EPS Growth | 12.0% | 12.0% | -21.9% | 18.5% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
59.9%
EPS terminal req.
$1.15
Spread vs growth
-47.9%
5Y implied EPS CAGR
37.7%
EPS terminal req.
$1.39
Spread vs growth
-25.7%
10Y implied EPS CAGR
23.1%
EPS terminal req.
$2.23
Spread vs growth
-11.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.0%
Start / end P/E
56.0x → 46.1x
EPS bridge
0.25 → 0.28
Residual
-2.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.